Related Experiment Video
Updated: Jul 6, 2026

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation
Published on: August 21, 2019
Heat-shock protein-based vaccines for cancer and infectious disease
1University of Pittsburgh, E1051, BSTWR, 200 Lothrop Street, Pittsburgh, PA 15261, USA. rjb42@pitt.edu
Abstract:
Almost 60 years ago, the pioneering work of George Klein and others showed that cancers could be made targets for the immune system. Identification of the tumor targets, known as tumor antigens, became a focus in cancer biology that led to the discovery of the immunological properties of heat-shock proteins (HSPs) in 1986 by Pramod Srivastava and colleagues. Since then, the use of HSPs in the therapeutics of cancer and infectious disease in several clinical trials has been guided by our understanding of the role and effects of HSPs in adaptive and innate immune responses, investigated primarily in mice. This review will highlight the immunological properties of HSPs as we understand them today and review the clinical work on human cancers. Several Phase I and II clinical trials in different types of cancer that have been completed, as well as ongoing Phase III trials, will be summarized.
Insights
Heat-shock proteins (HSPs) are crucial tumor targets for the immune system. This review summarizes HSPs
Area of Science:
- Immunology
- Oncology
- Biochemistry
Background:
- Pioneering work demonstrated that cancers can be targeted by the immune system.
- Discovery of heat-shock proteins (HSPs) in 1986 revealed their immunological properties.
- Understanding HSPs' roles in immune responses guides their therapeutic applications.
Purpose of the Study:
- To review the immunological properties of heat-shock proteins (HSPs).
- To summarize clinical trials using HSPs for human cancer therapy.
- To highlight ongoing and completed Phase I, II, and III clinical trials.
Main Methods:
- Review of existing literature on HSP immunology and cancer biology.
- Analysis of data from completed and ongoing clinical trials involving HSPs.
- Focus on studies investigating HSPs' effects on adaptive and innate immunity.
Main Results:
- HSPs possess significant immunological properties relevant to cancer therapy.
- Clinical trials have explored HSPs in various cancer types with promising outcomes.
- Ongoing trials continue to evaluate the efficacy and safety of HSP-based treatments.
Conclusions:
- Heat-shock proteins are vital targets for cancer immunotherapy.
- Clinical evidence supports the therapeutic potential of HSPs in treating human cancers.
- Further research and clinical trials are essential to optimize HSP-based cancer treatments.
Related Concept Videos
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Tumor Immunotherapy
Vaccines
Bacterial Protein Maturation
Vaccinations
Other Stress Responses in Bacteria

